• BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival
  
• UniQure shares crash 40% as FDA rejects early approval path for Huntington's gene therapy
  
• Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates
  

[AI Generated AI in Pharma News]

• Lilly debuts Nvidia supercomputer with fanfare and focus on escaping traditional pharma lifecycle
• Earendil pens $885M pact to use WuXi XDC's linker tech for next-gen ADCs
• XtalPi's AI + Robotics Platform Powers First Clinical Milestone for ReviR's Rare Neurological Drug RTX-117

[AI Generated Pharma and Biotech News]

• United Therapeutics' phase 3 win tees up filing to challenge J&J in cardiac condition
• FDA fully releases clinical hold on Intellia CRISPR gene therapy
• Earendil pens $885M pact to use WuXi XDC's linker tech for next-gen ADCs

[AI Generated AI in Pharma and Biotech News]

• QScreen AI secured CAD 500,000 in financing to expand its AI and quantum-driven health screening solutions across North America and Mexico.

• Investment is surging in the health insurance sector, highlighted by Handl Health’s $14.2 million Series A funding for AI tools that streamline underwriting and claims management.

• Roche and Insilico Medicine (in collaboration with Pfizer) are leading a shift toward AI-driven drug discovery, using deep learning and generative AI to identify therapeutic candidates and optimize protein engineering.

[AI Generated Pharma News]

• Earendil Labs and WuXi XDC have partnered to integrate machine learning with the WuXiTecan-2 platform to optimize the design and targeting precision of antibody-drug conjugates (ADCs).

• ImmVira is expanding clinical trials for MVR-T3011, a genetically engineered oncolytic virus, to treat BCG-naïve bladder cancer patients as a dual-action alternative to traditional therapies.
• Protagonist Therapeutics exited its profit-sharing deal with Takeda for the drug rusfertide, accepting a $400 million one-time payment to independently fund its broader pipeline, including the asset ICOTYDE™.

[AI Generated Pharma News]

• Pfizer has acquired the Chinese commercialization rights for Sciwind’s GLP-1 drug, ecnoglutide, in a deal valued at up to $495 million to target the region's growing metabolic disorder market.

• GSK is expanding its respiratory and cardiovascular pipeline through a $950 million acquisition of 35Pharma, gaining access to a promising activin signaling inhibitor for pulmonary hypertension.

• Novo Nordisk has entered a potential $2.1 billion partnership with Vivtex to leverage proprietary technology for developing oral formulations of biologic drugs like GLP-1 therapies.

[AI Generated AI in Drug Discovery News]

• Dimension has secured $500 million to fund approximately 24 companies, aiming to integrate computational power with life sciences to accelerate drug discovery.
• The BiopharmaTrend 2026 watchlist identifies startups founded in 2021 that are using AI platforms to move away from single-asset strategies toward more precise, platform-based drug development.
• Y Combinator is backing the Yale spinout Patientdesk.ai, which utilizes "Agentic AI" to eliminate inefficiencies and improve data-driven forecasting within clinical trials.

[AI Generated AI in Drug Discovery News]

• Turbine is utilizing a recently secured $25 million in Series B funding to advance its "lab-in-the-loop" AI platform that simulates biological processes to reduce the cost and risk of drug discovery.

• Evinova has established strategic partnerships with AstraZeneca, Astellas, and Bristol Myers Squibb to integrate AI across the drug development spectrum, focusing on clinical trial data analysis and early-stage candidate selection.

• Owkin has launched K Pro, an AI co-pilot that uses federated learning and biological reasoning to analyze fragmented biomedical data, aiming to significantly accelerate drug discovery timelines and enhance precision medicine.

[AI generated Pharma News]

• Turbine's Virtual Lab: The Hungary-based firm raised $25 million to scale its AI platform that simulates cellular biology to accelerate drug discovery.
• Global Licensing Surges: Highlighting Chinese expansion, Frontier signed a $1 billion kidney disease deal with GSK, while Harbour BioMed penned a $1.2 billion cancer treatment agreement with Solstice.
• Astellas & Vir Partnership: A $1.7 billion collaboration focuses on VIR-5500, a prostate cancer therapy that demonstrated a 45% response rate in early trials.